Joel Ackerman has filed a Form 4 with the SEC, indicating a change in his beneficial ownership of securities. This filing, dated October 16, 2026, is significant as it reflects Ackerman's current investment strategies and could influence market perceptions.
Background
Joel Ackerman is associated with Champions Oncology, Inc., a company operating within the biotechnology sector. The firm specializes in biological products, specifically those that do not include diagnostic substances. The recent filing is part of Ackerman's ongoing disclosures, with previous filings dating back to May 2026.
What the Filing Says
The filing states that the report period is October 15, 2026. However, specific details regarding the changes in ownership were not disclosed in the filing.
Impact
This update may affect stakeholders in Champions Oncology, as well as other companies in the biotechnology sector. Investors and analysts will likely scrutinize Ackerman's moves for insights into market trends and potential shifts in investor sentiment.
What's Next
The filing does not say what happens next.
Filing Details
The Form 4 filing indicates that it was accepted by the SEC on the same day it was filed, October 16, 2026, at 12:45:18 PM. This timely acceptance reflects the regulatory body's efficiency in processing ownership change reports.
Company Information
Champions Oncology, Inc. is incorporated in Delaware and has a fiscal year ending on April 30. The company is classified under the Standard Industrial Code (SIC) 2836, which pertains to Biological Products, specifically those that do not include diagnostic substances. This classification highlights the company's focus within the biotechnology sector.
Contact Information
Joel Ackerman's mailing address is listed as 855 N. Wolfe Street, Suite 619, Baltimore, MD 21205. This is also the business address for Champions Oncology, indicating a close operational relationship between Ackerman and the company.
Additional Context
The filing does not provide specific details about the nature of the changes in beneficial ownership, such as whether the changes involved purchases, sales, or other transactions. Furthermore, it does not disclose the number of shares affected or the price at which any transactions occurred, leaving investors without crucial information that could influence their assessments of Ackerman's investment strategy.